Fragile X syndrome is the most common inherited cause of cognitive disability and is the result of a mutation in the fragile X messenger ribonucleoprotein 1 (FMR1) gene.
On this page:
Epidemiology
Although the degree of cognitive disability is typically more severe in males with fragile X syndrome, females can also be affected. The estimated frequency of fragile X syndrome is 1/4000 males and 1/7000 females 3.
Clinical presentation
Affected individuals demonstrate a variety of cognitive disabilities and physical changes 3.
-
cognitive
variable cognitive disability ranging from mild to severe
autistic features
seizures
Prader-Willi phenotype (not Prader-Willi syndrome which is genetically distinct)
-
musculoskeletal
hypermobility
velvet-like skin
-
cardiovascular vascular
-
facial dysmorphism
long narrow faces
large ears
-
reproductive system
macroorchidism (males)
Pathology
The underlying genetic abnormality is an expansion of a trinucleotide repeat (CGG) in the 5` untranslated region fragile X messenger ribonucleoprotein 1 (FMR1) gene that encodes for the fragile X messenger ribonucleoprotein (FMRP) 1-3. This repeat is inherently unstable and can result in an expansion of the repeat during maternal transmission 3.
Based on the number of repeats FMR1 genes can be divided into three groups that correlate with phenotype 1-3.
5-54 repeats: normal population
55-200 repeats: premutation
>200 repeats: fragile X syndrome
Permutation
When 55-200 repeats are present there are excessive levels of FMR1 mRNA transcription but despite this, the actual levels of FMRP are reduced 3. Generally, most premutation carriers are phenotypically normal, however, approximately 25% demonstrate some subtle physical changes 2. Emotional difficulties are also reported 2. Specific sex-dependent phenotypic manifestations are also encountered:
-
females: primary ovarian insufficiency
found in approximately 20% of female premutation carriers
Fragile X syndrome
Once more than 200 repeats are present a cascade of events takes place resulting in the eventual methylation of the promoter region of the FMR1 gene which in turn silences the gene resulting in a lack of FMRP and resultant fragile X syndrome 2,3.
Radiographic features
Imaging will depend on the specific manifestations of the syndrome in an individual (see above).
Treatment and prognosis
At this time there are no accepted gene therapies or FMRP replacement therapies available, although both approaches are being researched.
Management is therefore targetted at the various manifestations of fragile X syndrome.
History and etymology
Previously named "fragile X mental retardation 1" gene, the gene responsible for fragile X syndrome was renamed in 2021 by the European Fragile X Network to "fragile X messenger ribonucleoprotein 1" 5. This was to remove the stigmatising language associated with the previous naming of the gene.